2 weeks Ago By Defense World Staff
Tandem Diabetes Care, Inc. ( NASDAQ:TNDM – Get Free Report ) has received a consensus rating of “Moderate Buy” from the eighteen analysts that are currently covering the firm, MarketBeat.com reports.
Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $54.25.
TNDM has been the subject of a number of recent research reports. UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a research note on Friday, August 2nd. Wells Fargo & Company upped their target price on shares of Tandem Diabetes Care from $50.
00 to $55.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. The Goldman Sachs Group started coverage on shares of Tandem Diabetes Care in a research note on Friday, October 4th.
They set a “neutral” rating and a $46.00 price target on the stock. Canaccord Genuity Group began coverage on Tandem Diabetes Care in a research note on Thursday, August 8th.
They issued a “buy” rating and a $57.00 price objective for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $55.
00 target price (up from $50.00) on shares of Tandem Diabetes Care in a report on Friday, August 2nd. Check Out Our Latest Research Report on TNDM Tandem Diabetes Care Trading Down 3.
6 % Tandem Diabetes Care ( NASDAQ:TNDM – Get Free Report ) last posted its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.
43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.
84% and a negative return on equity of 44.19%. The business had revenue of $243.
97 million for the quarter, compared to analysts’ expectations of $224.14 million. During the same quarter in the prior year, the business earned ($0.
38) EPS. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year.
On average, sell-side analysts predict that Tandem Diabetes Care will post -1.73 EPS for the current year. Institutional Trading of Tandem Diabetes Care A number of institutional investors and hedge funds have recently bought and sold shares of TNDM.
Brooklyn Investment Group bought a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $28,000. Assetmark Inc. bought a new position in Tandem Diabetes Care during the third quarter valued at approximately $29,000.
ORG Wealth Partners LLC purchased a new position in Tandem Diabetes Care during the 3rd quarter valued at approximately $30,000. ORG Partners LLC purchased a new position in Tandem Diabetes Care during the 2nd quarter valued at approximately $31,000. Finally, Headlands Technologies LLC bought a new stake in Tandem Diabetes Care in the 1st quarter worth approximately $35,000.
Tandem Diabetes Care Company Profile ( Get Free Report Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. See Also Five stocks we like better than Tandem Diabetes Care Following Congress Stock Trades 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick What is the Dow Jones Industrial Average (DJIA)? Mouse Rising: The Iger Investment Pays Off for Disney Investors CD Calculator: Certificate of Deposit Calculator Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.
com's FREE daily email newsletter ..
